Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles

Pharmaceutical Research

Volumn 20, Issue 3, 2003, Pages 409-416

  Kreuter, Jörg ^a   Ramge, Peter ^a,b   Petrov, Valery ^g   Hamm, Stefan ^c   Gelperina, Svetlana E ^a,d   Engelhardt, Britta ^c   Alyautdin, Renad ^g   Von Briesen, Hagen ^e   Begley, David J ^f  

^a GOETHE UNIVERSITY   (Germany)

^b Boots Healthcare Deutschland GmbH   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d Moscow Research Institute of Medical Ecology   (Russian Federation)

^e INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g NONE

Author keywords

Blood brain barrier; CNS drug delivery; Nanoparticles; Poly(butylcyanoacrylate)

Indexed keywords

ENBUCRILATE; INULIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; NANOPARTICLE; POLYSORBATE 80; SUCROSE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CATTLE; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BINDING; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY;

ANALGESICS, OPIOID; ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CATTLE; CELLS, CULTURED; DRUG CARRIERS; ENBUCRILATE; ENDOTHELIUM, VASCULAR; ENKEPHALIN, LEUCINE-2-ALANINE; HUMANS; MALE; MICE; MICE, INBRED ICR; MICROSCOPY, ELECTRON; MODELS, BIOLOGICAL; NANOTECHNOLOGY; PARTICLE SIZE; POLYSORBATES; RATS;

EID: 0037335187     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022604120952     Document Type: Article

References (25)

1. R. Alyautdin, D. Gothier, V. Petrov, D. Kharkevich, and J. Kreuter. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41:44-48 (1995).
2. R. N. Alyautdin, V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter. Delivery of loperamide across the blood-brain barrier with poly-sorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:325-328 (1997).
3. R. N. Alyautdin, E. B. Tezikov, P. Ramge, D. A. Kharkevich, D. J. Begley, and J. Kreuter. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15:67-74 (1998).
4. A. E. Gulyaev, S. E. Gelperina, I. N. Skidan, A. S. Antropov, G. Y. Kivman, and J. Kreuter. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16:1564-1569 (1999).
5. A. Friese, E. Seiler, G. Quack, B. Lorenz, and J. Kreuter. Enhancement of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release delivery system. Eur. J. Pharm. Biopharm. 49:103-109 (2000).
6. D. J. Begley, M. W. Bradbury, and J. Kreuter (eds.). The Blood-Brain Barrier and Drug Delivery to the CNS, Marcel Dekker, New York. 2000.
7. A. Minn, R. D. S. El-Bachá, C. Bayol-Denizot, P. Lagrange, and F. G. Suleman. Drug metabolism in the brain: Benefits and risks. In D. J. Begley, M. W. Bradbury, and J. Kreuter (eds.) The Blood-Brain Barrier and Drug Delivery to the CNS, Marcel Dekker, New York, 2000, pp. 145-170.
8. J.-C. Olivier, L. Fenart, R. Chauvet, C. Pariat, R. Cecchelli, and W. Couet. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16:1836-1842 (1999).
9. E. I. Kalenikova, O. F. Dimittriekova, S. V. Zhukova, and V.A. Tishenko. Farmokinetica dalargina. Vopr. Med. Khim. 34:75-83 (1988).
10. P. Ramge, J. Kreuter, and B. Lemmer. Circadian phase-dependent antinociceptive reaction in mice after i. v. injection of dalargin-loaded nanoparticles determined by the hot-plate test and the tail-flick test. Chronobiol. Int. 17:767-777 (1999).
11. R. Cecchelli, B. Dehouck, L. Descamps, L. Fenart, V. Buée-Scherrer, C. Duhem, S. Lundquist, M. Rentfel, G. Torpier, and M. P. Dehouck. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36:165-178 (1999).
12. P. Ramge, R. E. Unger, J. B Oltrogge, D. Zenker, D. Begley, J. Kreuter, and H. von Briesen. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci. 12:1931-1940 (2000).
13. K. R. Dorovini-Zis, R. Prameya, and P. D. Bowman. Culture and characterisation of microvascular endothelial cells derived from human brain. Lab. Invest. 64:425-436 (1991).
14. S. Méresse, M. P. Dehouck, P. Delorme, M. Bensaid, J. P. Tauber, C. Delbart, J. C. Fruchard, and R. Cecchelli. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J. Neurochem. 53:1363-1371 (1989).
15. J. Boother and M. Sensenbrenner. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 2:97-105 (1972).
16. A. Siflinger-Birnboim, P. J. Del Vecchio, J. A. Cooper, F. A. Blumenstock, J. N. Shepard, and A. B. Mailk. Molecular sieving characteristics of the cultured endothelial monolayer. J. Cell. Physiol. 132:111-117 (1987).
17. M.-P. Dehouck, S. Méresse, P. Delorme, J. C. Fruchart, and R. Cecchelli. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 54:1798-1801 (1990).
18. M.-P. Dehouck, P. Jolliet-Riant, F. Bree, J.-C. Fruchart, R. Cecchelli, and J.-P. Tillement. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J. Neurochem. 58:1790-1797 (1992).
19. T. J. Raub, S. L. Kuentzel, and G.A Sawada. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astroglioma cells. Exp. Cell Res. 199:330-340 (1992).
20. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171-174 (1995).
21. J. Kreuter and R. N. Alyautdin. Using nanoparticles to target drugs to the central nervous system. In D. J. Begley, M. W. Bradbury, and J. Kreuter (eds.), The Blood-Brain Barrier and Drug Delivery to the CNS, Marcel Dekker, New York, 2000, pp. 205-223.
22. R. N. Alyautdin, A. Reichel, R. Löbenberg, P. Ramge, J. Kreuter, and D. J. Begley. Interaction of poly(butylcyanoacrylate) nano-particles with the blood-brain barrier in vivo and in vitro. J. Drug Target. 9:209-221 (2001).
23. B. Kante. G Couvreur, C. Dubois-Krack, P. De Meester, M. Guiot, M. Roland, and P. Spieser. Toxicity of polyalkylcyanoacrylate nanoparticles 1: free nanoparticles. J. Pharm. Sci. 71:786-790 (1982).
24. S. E Gelperina, A. S. Khalansky, I. N. Skidan, Z. S. Smirnova, A. I. Bobruskin, S. E. Severin, B. Turowski, F. E. Zanella, and J. Kreuter. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126:131-141 (2002).
25. U. Schroeder and B. A. Sabel. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710:121-124 (1996).